Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 1/20 | 0.50 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.50 |
| ▸ | KIT | P10721 | 6/20 | 0.44 |
| ▸ | ULK1 | O75385 | 10/20 | 0.42 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.41 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15020477 | 0.88 | BRD4 (0.49) | LPLLIPGKITULK1CCNB2 | |
| SCHEMBL15020861 | 0.82 | ORAI1 (0.41) | LPLLIPGKITGSK3AGSK3B | |
| SCHEMBL15020881 | 0.78 | ORAI1 (0.52) | LPLLIPGGSK3AGSK3B | |
| SCHEMBL2969113 | 0.76 | BRD4 (0.43) | LPLLIPGGSK3AGSK3B | |
| SCHEMBL18952058 | 0.75 | CCNB2 (0.54) | KITULK1CCNB2CDK1CCNB1 | |
| SCHEMBL15020654 | 0.75 | PIK3C3 (0.36) | GSK3AGSK3B | |
| SCHEMBL15020517 | 0.75 | PIK3C3 (0.38) | LPLLIPGKITGSK3AGSK3B | |
| SCHEMBL15751423 | 0.75 | GSK3A (0.38) | LPLLIPGGSK3AGSK3B | |
| SCHEMBL16977987 | 0.74 | KIT (0.55) | KITULK1CCNB2CDK1CCNB1 | |
| SCHEMBL15020658 | 0.74 | PDGFRB (0.34) | LPLLIPGKITGSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250042895-A1 | INHIBITORS OF ULK1 AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2025-02-06 | — | — | US | disclosed |
| WO-2023059786-A1 | INHIBITORS OF ULK1 AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042895-A1 | INHIBITORS OF ULK1 AND METHODS OF USE | ULK1, ULK2, ULK3 | LPL 4038/4885LIPG 2235/4885KIT 2073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.